IOPen underestimates IOP measurements

Article

The IOPen rebound tonometer underestimates intraocular pressure (IOP) measurements compared to Goldmann applanation tonometer (GAT) and ocular response analyzer (ORA).

The IOPen rebound tonometer underestimates intraocular pressure (IOP) measurements compared to Goldmann applanation tonometer (GAT) and ocular response analyzer (ORA), reveals a study published in Eye.

Dr J. Moreno-Montañés et al., Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain, conducted a cross-sectional, randomized study on 198 normal eyes. The Bland and Altman limits of agreement (LoA) were used to calculate agreement between all three tonometers.The median IOPen IOP was 3 mm Hg below the GAT and the ORA IOP. LoA width between the IOPs of the IOPen and the GAT ranged between 13.92 and 15.99 mm Hg. Central corneal thickness (CCT) was not linked to the IOPen measurements, but corneal hysteresis (CH) and corneal rigidity factor (CRF) were linked to measurements by IOPen and GAT.

IOPen underestimated the IOP compared with GAT and ORA. The effect of measurement quality or measurement order on IOPen was low. CCT did not affect the IOPen, but the CH and CRF did. The LoA width between the IOPen and GAT IOPs was higher than between the ORA IOPg or ORA IOPcc and GAT IOPs.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.